HTG Molecular Diagnostics has appointed Ann Hanham to its board of directors. Hanham is a founding and managing partner of BAR Capital Management. She currently serves on two other public company boards, and has served on the boards of 20 global companies, both private and public. From February 2000 to November 2013, she served as managing director and general partner of Burrill & Company. Prior to that, Hanham held positions in clinical and regulatory affairs, and product development at various companies, including InterMune, Otsuka America Pharmaceuticals, Celtrix Pharmaceuticals, and Becton Dickinson.